What is Valiant Laboratories Ltd. Quarterly Revenue?

Valiant Laboratories Ltd. Quarterly Revenue Valiant Laboratories Sep-2026 Quarterly Revenue is Rs 73 Cr which is growth of 55.5% YoY.

What is Valiant Laboratories Ltd. Quarterly Net Profit?

Valiant Laboratories Ltd. Quarterly Net Profit Valiant Laboratories Sep-2026 Quarterly Net Profit is Rs 1 Cr which is growth of 772.5% YoY.

What is Valiant Laboratories Ltd. Annual Revenue?

Valiant Laboratories Ltd. Annual Revenue Valiant Laboratories Mar-2026 Annual Revenue is Rs 220 Cr which is growth of 58.5% YoY.

What is Valiant Laboratories Ltd. Annual Net Profit?

Valiant Laboratories Ltd. Annual Net Profit Valiant Laboratories Mar-2026 Annual Net Profit is Rs 6 Cr which is growth of 358.0% YoY.

What is Valiant Laboratories Ltd. Total Shareholders Fund?

Valiant Laboratories Ltd. Total Shareholders Fund Valiant Laboratories Mar-2026 Total Shareholders Fund is Rs 320 Cr which is growth of 36.4% YoY.

What is Valiant Laboratories Ltd. Total Assets?

Valiant Laboratories Ltd. Total Assets Valiant Laboratories Mar-2026 Total Assets is Rs 386 Cr which is growth of 21.6% YoY.

What is Valiant Laboratories Ltd. Book Value Per Share?

Valiant Laboratories Ltd. Book Value Per Share Valiant Laboratories Mar-2026 Book Value Per Share is 59 Rs which is growth of 9.1% YoY.

What is Valiant Laboratories Ltd. ROE?

Valiant Laboratories Ltd. ROE Valiant Laboratories Mar-2026 ROE is 2% which is growth of 2.6% YoY.

What is Valiant Laboratories Ltd. Cash From Operating Activity?

Valiant Laboratories Ltd. Cash From Operating Activity Valiant Laboratories Mar-2026 Cash From Operating Activity is Rs -14 Cr which is growth of 37.0% YoY.

What is Valiant Laboratories Ltd. Net Cash Flow?

Valiant Laboratories Ltd. Net Cash Flow Valiant Laboratories Mar-2026 Net Cash Flow is Rs -2 Cr which is growth of -167.1% YoY.

Valiant Laboratories Ltd.

NSE: VALIANTLAB | BSE: 543998

Strong Performer, Getting Expensive

Download real time

-2.51(-1.99%)

149.10% Gain from 52W Low

9,913

NSE+BSE Volume

NSE 03 Nov, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting

The latest board meeting for Valiant Laboratories took place on 02 Nov 2026, for the purpose of Quarterly Results See details

Valiant Laboratories quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Valiant Laboratories quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

POSITIVE
Quarterly Revenue Valiant Laboratories Sep-2026 Quarterly Revenue is Rs 73 Cr which is growth of 55.5% YoY.
POSITIVE
Quarterly Net Profit Valiant Laboratories Sep-2026 Quarterly Net Profit is Rs 1 Cr which is growth of 772.5% YoY.

Valiant Laboratories Ltd., Quarterly, standalone, All financials are in INR Cr and price data in INR
Indicator	Sep '26	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23
TOTAL_SR_Q Total Rev. ⌄	72.9	74.3	66.1	55.4	46.8	51.7	58.4	35.9	23.4	21.1	33.1	42.3	62.5
SR_Q Operating Rev.	72.4	73.4	65.3	54.7	46	51	57.8	35.2	21.5	18.9	30.6	40.5	59.6
OI_Q Other Income	0.4	0.9	0.8	0.6	0.9	0.7	0.7	0.7	1.9	2.2	2.5	1.8	3
OEXPNS_Q Operating Exp.	70.3	60.9	60.8	54.5	45.9	48.7	53.9	34.6	28.2	21.3	35.1	46.8	60.9
OEXPNS_Q Operating Exp.	70.3	60.9	60.8	54.5	45.9	48.7	53.9	34.6	28.2	21.3	35.1	46.8	60.9
OP_Q Operating Profit	2.1	12.5	4.5	0.3	0.1	2.4	3.8	0.6	-6.7	-2.4	-4.5	-6.3	-1.4
OPMPCT_Q Operating Profit Margin %	2.95%	17.02%	6.89%	0.46%	0.13%	4.63%	6.63%	1.77%	-31.38%	-12.65%	-14.81%	-15.57%	-2.33%
DEP_Q Depr.	0.6	0.6	0.5	0.7	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
INT_Q Interest	0.1	0.1	0	0	0.1	0.1	0.1	0.1	0	0.1	0	0	0
PBT_Q Profit Before Tax	1.9	12.7	4.7	0.1	0.3	2.5	3.9	0.7	-5.3	-0.8	-2.6	-5	1.1
TAX_Q Tax	0.4	3.3	1.2	0.1	0.1	0.6	0.7	-0.9	0.7	0.2	-1.3	-1.5	0.3
NP_Q Net Profit	1.5	9.5	3.5	0	0.2	1.8	3.2	1.6	-6	-1	-1.2	-3.5	0.8
EPS_adj_Q EPS Adj. latest	0.3	1.8	0.7	0	0	0.3	0.6	0.3	-1.1	-0.2	-0.2	-0.6	0.2
NP_TTM Net profit TTM	14.5	13.2	5.6	5.3	6.8	0.7	-2.2	-6.6	-11.7	-4.9	0.3	9.4	20.5
EPS_TTM Basic EPS TTM	2.7	2.4	1	1	1.3	0.2	-0.5	-1.5	-2.7	-1.1	0.1	2.2	6.3
results_pdf Results PDF
result_notes Result Notes	Notes	Notes	Notes	Notes	Notes	Notes		Notes	Notes	Notes	Notes	Notes	Notes

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Valiant Laboratories competitor comparison and performance snapshot within industry

Valiant Laboratories annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue Valiant Laboratories Mar-2026 Annual Revenue is Rs 220 Cr which is growth of 58.5% YoY.
POSITIVE
Annual Net Profit Valiant Laboratories Mar-2026 Annual Net Profit is Rs 6 Cr which is growth of 358.0% YoY.

Valiant Laboratories Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21
SR_A Total Rev. Ann. ⌄	-13.4%	3.7%	268.5	219.9	138.8	191.7	338.8	293.5	183.8
TotalOperatingRevenues_A Operating Rev. Ann.	-13.4%	3.5%	265.9	217	133.4	182.1	333.9	291.5	182.4
OI_A Other Income Ann.	-16%	15.7%	2.6	2.9	5.4	9.7	4.9	2	1.4
OEXPNS_A Operating Exp. Ann.	-11.1%	9.7%	246.5	209.9	138	190.5	298.8	249.2	132.4
OEXPNS_A Operating Exp. Ann.	-11.1%	9.7%	246.5	209.9	138	190.5	298.8	249.2	132.4
OP_A Operating Profit Ann.	-41%	-32.1%	19.4	7.2	-4.7	-8.4	35.1	42.3	50
OPMPCT_A OPM Ann. %	-32%	-34.6%		3.26%	-3.37%	-4.39%	10.36%	14.42%	27.21%
TotalExpenses_A Total Exp. Ann. ⌄	-10.9%	9.2%		212.4	140.2	192.5	300.6	251.8	136.8
OtherExpenses_A Other Exp. Ann.	23.3%	25.7%	16.6	17.6	10.9	8.4	9.4	6.9	5.6
EmployeeBenefitExpenses_A Employee Exp. Ann.	2.8%	13.1%	5.3	5	4.4	4.3	4.6	3.1	2.7
CostOfPowerPurchased_A Cost Of Power Purchased Ann.	-	-
CostOfFuel_A Cost Of Fuel Ann.	-	-
EBIDT_A EBITDA Ann.	-36.8%	-27.8%		10.1	0.8	1.3	40	44.3	51.4
EBIDTPCT_A EBITDA Ann. margin %	-27%	-30.4%		4.58%	0.54%	0.66%	11.79%	15.08%	27.98%
INT_A Interest Ann.	0%	-30.1%	0.2	0.3	0.2	0.1	0.3	0.1	1.8
DEP_A Depr.	12.9%	-2.4%	2.3	2.3	2	2	1.6	2.5	2.6
PBT_A PBT Ann.	-41.6%	-30.5%	19.5	7.6	-1.5	-0.8	38.1	41.7	47
TAX_A Tax Ann.	-39.7%	-34.3%	5	2	0.7	-1.1	9.1	14.2	16.4
PAT_A PAT Before ExtraOrdinary Items Ann. ⌄	-42.2%	-28.8%		5.6	-2.2	0.3	29	27.5	30.6
IncomeMinorityInterest_A Minority Interest Income Ann.	-	-		-	-	-	-	-	-
NP_A Net Profit Ann.	-42.2%	-28.8%	14.5	5.6	-2.2	0.3	29	27.5	30.6
NETPCT_A NPM Ann. %	-33.5%	-31.4%		2.55%	-1.61%	0.18%	8.68%	9.43%	16.77%
EPS_adj_A EPS Adj. latest Ann.	-42.6%	-29.1%		1	-0.4	0.1	5.3	5.1	5.6
result_notes Result Notes				Notes		Notes
Annual_Reports Annual Reports

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

58.4%

2Y CAGR

7.1%

3Y CAGR

-13.4%

5Y CAGR

3.7%

Total Revenue Annual growth is higher than historical averages.

Net Profit Ann.

2Y CAGR

332%

3Y CAGR

-42.2%

5Y CAGR

-28.8%

Net Profit Annual growth is higher than historical averages.

Operating Exp. Ann.

1Y CHG

52.1%

2Y CAGR

3Y CAGR

-11.1%

5Y CAGR

9.7%

Operating Expenses Annual Cr growth is higher than historical averages.

Valiant Laboratories balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Total Shareholders Fund Valiant Laboratories Mar-2026 Total Shareholders Fund is Rs 320 Cr which is growth of 36.4% YoY.
POSITIVE
Total Assets Valiant Laboratories Mar-2026 Total Assets is Rs 386 Cr which is growth of 21.6% YoY.

Valiant Laboratories Ltd., Balance Sheet, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	47.1%	29.3%	319.8	234.4	236.9	100.5	71.5	88.6
EQCAP_A Equity Share Capital Ann.	18.5%	38.9%	54.3	43.5	43.5	32.6	16.3	10.5
TotalShareCapital_A Total Share Capital Ann.	18.5%	38.9%	54.3	43.5	43.5	32.6	16.3	10.5
ReservesAndSurplus_A Reserves Plus Surplus Ann.	57.5%	27.7%	265.5	190.9	193.4	67.9	55.2	78.1
TotalReservesAndSurplus_A Total Reserves Plus Surplus Ann.	57.5%	27.7%	265.5	190.9	193.4	67.9	55.2	78.1
LiabilityMinorityInterest_A Minority Interest Liability Ann.	-	-	-	-	-	-	-	-
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann. ⌄	-61.6%	14.2%	3.5	62	61.5	61.8	60.9	1.8
DeferredTaxLiabilities_A Deferred Tax Liabilities Ann.	31.7%	21.7%	1.6	1.3	0.6	0.7	0.3	0.6
OtherLongTermLiabilities_A Other LongTerm Liabilities Ann.	4%	12.5%	1.8	1.2	1.4	1.6	1.2	1
CL_A Total Current Liabilities Ann. ⌄	7.5%	31.6%	62.7	21	26.4	50.5	49.4	15.9
TradePayables_A Trade Payables Ann.	8.4%	37.4%	60.2	19.4	24.8	47.3	46.4	12.3
OtherCurrentLiabilities_A Other Current Liabilities Ann.	-9.5%	-7.5%	2.3	1.4	1.5	3.1	1.6	3.4
ShortTermProvisions_A ST Provisions Ann.	26%	14.9%	0.2	0.1	0.1	0.1	0.2	0.1
TL_A Total Capital Plus Liabilities Ann.	21.9%	29.4%	385.9	317.3	324.7	212.8	181.8	106.3
FixedAssets_A Fixed Assets Ann. ⌄	0%	8.7%	30	30.2	31.8	30	23.7	19.8
TangibleAssets_A Tangible Assets Ann.	-0.4%	8.4%	29.6	29.9	31.6	30	22.2	19.8
IntangibleAssets_A Intangible Assets Ann.	-	-	0.1	0.1
CapitalWorkInProgress_A Capital Work In Progress Ann.	58.7%	-	0.4	0.2	0.2	0.1	1.4
TotalNonCurrentAssets_A Total Non Current Assets Ann. ⌄	85.5%	57.3%	196.6	198.1	115.5	30.8	25	20.4
NonCurrentInvestments_A Non Current Investments Ann.	-	-	165.1	165.1	81	0
DeferredTaxAssets_A Deferred Tax Assets Ann.	-	-
LongTermLoansAndAdvances_A LT Loans Plus Advances Ann.	-	-
OtherNonCurrentAssets_A Other Non Current Assets Ann.	23.3%	20.1%	1.5	2.8	2.7	0.8	1.3	0.6
CA_A Total Current Assets Ann. ⌄	1.3%	17.1%	189.3	119.2	209.3	182	156.8	85.9
CurrentInvestments_A Current Investments Ann.	-8.6%	-	26		37.6	34	0.4
TradeReceivables_A Trade Receivables Ann.	-2%	14.4%	83.3	72.1	45.7	88.6	110.8	42.5
CashAndCashEquivalents_A Cash Plus Cash Equivalents Ann.	136.3%	-19%	6.6	27.3	96.7	0.5	20.1	18.9
ShortTermLoansAndAdvances_A ST Loans Plus Advances Ann.	-	-	0	0.1	0	32.4		0
OtherCurrentAssets_A Other Current Assets Ann.	55.2%	22.4%	50.5	15.8	19.2	13.5	9.7	18.4
TA_A Total Assets Ann.	21.9%	29.4%	385.9	317.3	324.7	212.8	181.8	106.3
ContingentLiabilities_A Contingent Liabilities plus Commitments Ann.	387.7%	-	46.4	76.1	16.7	0.4	0.9
BonusEquityShareCapital_A Bonus Equity Share Capital Ann.	0%	-	16.3	16.3	16.3	16.3	1.5
NonCurrentInvestmentsUnquotedBookValue_A Non Current Investments Unquoted Book Value Ann.	-	-				0
CurrentInvestmentsUnquotedBookValue_A Current Investments Unquoted Book Value Ann.	-	-

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Assets Ann.

1Y CHG

21.6%

2Y CAGR

3Y CAGR

21.9%

5Y CAGR

29.4%

Total Assets Annual growth is lower than historical averages.

Total Current Liabilities Ann.

1Y CHG

198.6%

2Y CAGR

54.1%

3Y CAGR

7.5%

5Y CAGR

31.6%

Total Current Liabilities Annual Cr growth is higher than historical averages.

Total ShareHolders Funds Ann.

1Y CHG

36.4%

2Y CAGR

16.2%

3Y CAGR

47.1%

5Y CAGR

29.3%

Total ShareHolders Funds Annual growth is stable compared to historical averages.

Valiant Laboratories ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Book Value Per Share Valiant Laboratories Mar-2026 Book Value Per Share is 59 Rs which is growth of 9.1% YoY.
POSITIVE
ROE Valiant Laboratories Mar-2026 ROE is 2% which is growth of 2.6% YoY.

Valiant Laboratories Ltd., Ratios, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21
BVSH_A BVSH Ann.	24%	-6.9%	58.9	53.9	54.5	30.9	43.9	84.4
ROA_A RoA Ann. %	-52.8%	-45.1%	1.43%	-0.67%	0.10%	13.62%	15.12%	28.77%
ROE_A ROE Ann. %	-60.9%	-45%	1.73%	-0.91%	0.14%	28.85%	38.47%	34.53%
ROCE_A ROCE Ann. %	-53.3%	-46.3%	2.41%	-0.42%	-0.22%	23.66%	31.55%	53.97%
ProfitabilityHeader Profitability Ratio ⌄
PBDITMargin_A EBITDA Ann. Margin %	-27.1%	-30.3%	4.64%	0.56%	0.69%	11.96%	15.18%	28.19%
PBITMargin_A EBIT Ann. Margin %	-32.1%	-33.1%	3.59%	-0.95%	-0.37%	11.49%	14.33%	26.76%
PBTMargin_A PBT Ann. Margin %	-32.8%	-33%	3.47%	-1.08%	-0.41%	11.42%	14.30%	25.78%
NETPCT_A NPM Ann. %	-33.5%	-31.4%	2.55%	-1.61%	0.18%	8.68%	9.43%	16.77%
ASETTO_A Asset Turnover Ann. %	-29.3%	-	0.6	0.4	0.7	1.7	2	-
LiquidityHeader Liquidity Ratio ⌄
CRATIO_A Current Ratio Ann.	-5.9%	-11.1%	3	5.7	7.9	3.6	3.2	5.4
QuickRatio_A Quick Ratio Ann.	-6.5%	-11.6%	2.7	5.5	7.6	3.3	2.9	5
DividendPayoutNP_A Dividend Payout to NP Ann.	-	-				-	-	-
EarningRetention_A Earning Retention Ann. %	-	-
CashEarningRetention_A Cash Earning Retention Ann. %	-	-
CashEarningRetention_A Cash Earning Retention Ann. %	-	-
ValuationHeader Valuation Ratio ⌄
EnterpriseValue_A EnterpriseValue Ann.	-	-	272.5	365.7	595.3
EVPerNetSales_A EV Per Net Sales Ann.	-	-	1.3	2.7	3.3	-	-	-
PBV_A Price To Book Value Adjusted	-19.5%	7.4%	2.09	2.12	2.26	4	2.81	1.46
EVPerEBITDA_A EV Per EBITDA Ann.	-	-	27.1	486.3	467.6	-	-	-
MarketCapPerSales_A Market Cap Per Sales Ann.	-	-	1.3	2.5	3.5	-	-	-
RetentionRatios_A Retention Ratio Ann. %	-	-
EYield_A Earnings Yield Ann.	-	-	0	-0
DEBT_CE_A Total Debt to Total Equity Ann.	-30.7%	-		0.3	0.3	0.6	0.9

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

ROE Ann. %

2Y CAGR

251.5%

3Y CAGR

-60.9%

5Y CAGR

-45%

ROE Annual % is growing faster than historical averages.

RoA Ann. %

2Y CAGR

278.2%

3Y CAGR

-52.8%

5Y CAGR

-45.1%

RoA Annual % is growing faster than historical averages.

Current Ratio Ann.

1Y CHG

-47.4%

2Y CAGR

-38.4%

3Y CAGR

-5.9%

5Y CAGR

-11.1%

Current Ratio Annual is falling faster than historical averages.

Valiant Laboratories cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Cash From Operating Activity Valiant Laboratories Mar-2026 Cash From Operating Activity is Rs -14 Cr which is growth of 37.0% YoY.
NEGATIVE
Net Cash Flow Valiant Laboratories Mar-2026 Net Cash Flow is Rs -2 Cr which is growth of -167.1% YoY.

Valiant Laboratories Ltd., Cash Flow, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21
CFO_A Cash from Operating Act. Ann. ⌄	-	-	-13.8	-21.9	48.8	23	2.3	9.1
PBT_A PBT Ann.	-41.6%	-30.5%	7.6	-1.5	-0.8	38.1	41.7	47
INT_A Interest Ann.	0%	-30.1%	0.3	0.2	0.1	0.3	0.1	1.8
TAX_A Tax Ann.	-39.7%	-34.3%	2	0.7	-1.1	9.1	14.2	16.4
CFI_A Cash from Investing Act. Ann.	-	-	-8.1	25	-182.7	-21.2	-12.2	-16.7
CFA_A Cash from Financing Act. Ann.	-	12.1%	20.2	-0.5	135.8	-1.5	6.2	11.4
NCF_A Net Cash Flow Ann. ⌄	-	-	-1.7	2.6	1.9	0.2	-3.8	3.9
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	263.4%	116.9%	4.8	2.2	0.4	0.1	3.9	0.1
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	97.9%	-4.5%	3.1	4.8	2.2	0.4	0.1	3.9

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Cash from Financing Act. Ann.

2Y CAGR

-61.4%

5Y CAGR

12.1%

Cash from Financing Annual Activity growth is higher than historical averages.

Valiant Laboratories investor presentations, annual reports, credit ratings, and earnings calls with AI summary, video, and audio access

Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow
Documents

Valiant Laboratories quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents